Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 16, 2007 David Meier	Select Comfort vs. Gilead Sciences: Select Comfort In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Despite its recent change of expectations, Select Comfort has all the tools to be a giant-killer.
The Motley Fool February 27, 2007 Brian Lawler	Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors.
The Motley Fool December 31, 2007 Brian Lawler	Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year.
The Motley Fool June 12, 2008 Brian Lawler	Gilead's Got the Goods As long as Gilead Sciences makes good use of its cash, its long-run future looks bright.
The Motley Fool July 21, 2010 Brian Orelli	15% Revenue Growth Is Good for Pfizer, but Not Gilead Gilead needs to reaccelerate growth.
The Motley Fool July 27, 2011 Brian Orelli	Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain.
The Motley Fool December 20, 2010 Brian Orelli	A Good Fit. On the Surface. Digging a little deeper into Gilead's acquisition of Arresto.
The Motley Fool October 20, 2010 Brian Orelli	What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back.
The Motley Fool September 6, 2007 Brian Lawler	Foolish Fantasy Football: Gilead Sciences on Offense For his fantasy football investment team, this stock analyst thinks Gilead packs enough offensive muscle to score in anyone's portfolio.
The Motley Fool May 30, 2008 Brian Lawler	Gilead Gets Synergistic Gilead Sciences newly acquired compound will play nicely with the drugmaker's existing products.
The Motley Fool March 26, 2007 Dan Caplinger	Chesapeake Energy vs. Altria: Altria In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Respecting its shareholders is how Big MO does business.
The Motley Fool February 18, 2010 Brian Orelli	Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues.
The Motley Fool March 31, 2011 Brian Orelli	Gilead's Long-Term Cancer Fight An academic partnership is a good sign it's serious.
The Motley Fool November 9, 2009 Dave Mock	A Big Upgrade for Gilead Sciences The biopharmaceutical company moves up to a five star rating from Motley Fool analysts.
The Motley Fool April 24, 2007 Brian Lawler	Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes.
The Motley Fool January 27, 2011 Brian Orelli	Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade.
The Motley Fool September 20, 2011 Brian Orelli	Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell?
The Motley Fool July 21, 2006 Brian Lawler	Gilead's Acquisitive Mood Trading at around 28 times 2006 EPS estimates, and with 40% growth expected for its HIV franchise, Gilead offers tempting value -- assuming it makes smart use of that cash sitting on the balance sheet.
The Motley Fool March 16, 2007 Dan Caplinger	ExxonMobil vs. Sasol: ExxonMobil In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Strike black gold with the biggest of Big Oil.
The Motley Fool February 23, 2010 Brian Orelli	The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston.
The Motley Fool July 18, 2008 Brian Lawler	Still Liking Gilead, Warts and All Don't look past a few issues, even though Gilead still has a bright future.
The Motley Fool March 15, 2007 Nathan Parmelee	Microsoft vs. Johnson & Johnson: Microsoft In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Both businesses have defensible moats, pay increasing dividends, and trade at a reasonable price.
Pharmaceutical Executive September 1, 2010	Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days?
The Motley Fool March 21, 2007 Dan Caplinger	Altria vs. AT&T: Altria In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Think about one thing: Which company will protect your investment better?
The Motley Fool June 25, 2010 Brian Orelli	Diversification Times 50,000 Gilead Sciences diversifies any way it can.
The Motley Fool January 6, 2010 Brian Orelli	Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data.
The Motley Fool December 16, 2009 Brian Orelli	Gilead's Phase 3 Train Wreck Gilead Sciences' darusentan looked so promising.
The Motley Fool May 24, 2011 Brian Orelli	J&J Approved, but Needs Help From a Friend The HIV combo product is the key.
The Motley Fool July 23, 2007 Brian Lawler	Gilead's Great Growth The drugmaker announces another great quarter of growth. Investors, take note.
The Motley Fool January 27, 2010 Brian Orelli	The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool March 21, 2007 Bill Mann	Marvel vs. New Oriental Education: New Oriental Education In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Get ready to get schooled, Marvel.
The Motley Fool January 25, 2008 Brian Lawler	What's Not to Like About Gilead? Gilead is looking more and more like a diversified pharma with a robust clinical-stage pipeline and growing cash flows.
The Motley Fool March 16, 2007 Matt Koppenheffer	Unilever vs. Diageo: Unilever In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." When there's something strange in the stock market -- who you gonna call? Unilever!
The Motley Fool July 17, 2009 Brian Orelli	Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson.
The Motley Fool March 29, 2010 Brian Orelli	5 Drugmakers Producing Cash for You Take greenbacks over earnings any day.
BusinessWeek February 19, 2007 Arlene Weintraub	How Gilead Primed The Pipeline Gilead's $2.5 billion purchase of Myogen offers instant diversification from its HIV drug focus.
The Motley Fool March 15, 2007 Philip Durell	Chesapeake Energy vs. Citigroup: Chesapeake Energy In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Benefit from this huge upside opportunity.
The Motley Fool September 19, 2008 Brian Lawler	FDA Tells Gilead to Take 1 More Step There's a small consolation prize for Gilead Sciences in this rejection from the FDA.
The Motley Fool March 16, 2007 Anders Bylund	AMD vs. Cisco: AMD In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Day traders and other short-termers sometimes present us with incredible long-term values.
The Motley Fool October 19, 2006 Brian Lawler	No Gilded Quarter for Gilead The company's recent acquisition may help it become a diversified drug giant. Investors, take note.
The Motley Fool February 5, 2007 Brian Lawler	Gilead's Gold Mine In the fourth quarter, the pharmaceutical continues to rake in the cash from its top products. Investors, take note.
BusinessWeek April 25, 2005 Sarah Lacy	BW50: Gilead's Big Growth Spurt The small biotech rivals the majors in HIV drugs. Now it must expand beyond its niche
The Motley Fool March 21, 2007 Ryan Fuhrmann	Sasol vs. Cisco: Cisco In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Cisco stands out in its field and against this company in a cyclical industry.
BusinessWeek September 18, 2006 Gene G. Marcial	Gilead Has "Room To Run" Most pharmaceutical companies are limping, but Gilead Sciences has sprinted.
The Motley Fool October 7, 2011 Brian Orelli	A Little Help, Please Gilead pumps up the pipeline.
The Motley Fool October 21, 2009 Brian Orelli	Double-Digit Growth in a Recession The strong double-digit growth at Gilead shouldn't be much of a surprise; HIV patients need their medication even in a recession.
The Motley Fool February 23, 2011 Brian Orelli	Gilead Gears Up to Fight Cancer Gilead has been infected by the diversification bug.
The Motley Fool March 22, 2006 Tim Hanson	Stock Madness 2006: Rage Against the Hype Machine Solid returns from solid companies are highlighted in this investing series based loosely on the annual NCAA College Basketball Tournament, a.k.a. "March Madness." Berkshire Hathaway... Valero... American Financial... etc.
The Motley Fool March 16, 2007 Ryan Fuhrmann	AMD vs. Cisco: Cisco In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Cisco dominates its industry and has little in the way of a peer to threaten its bright growth outlook and impressive annual cash-generation capabilities.